Sevoflurane inhibits the malignant potential of head and neck squamous cell carcinoma via activating the hypoxia‑inducible factor-1α signaling pathway in vitro

Yang,Yaqiong; Hu,Rong; Yan,Jia; Chen,Zhifeng; Lu,Yi; Jiang,Jue; Jiang,Hong

doi:10.3892/ijmm.2017.3306

Sevoflurane inhibits the malignant potential of head and neck squamous cell carcinoma via activating the hypoxia‑inducible factor-1α signaling pathway in vitro

Authors:
- Yaqiong Yang
- Rong Hu
- Jia Yan
- Zhifeng Chen
- Yi Lu
- Jue Jiang
- Hong Jiang
View Affiliations

Affiliations: Department of Anesthesiology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Center for Specialty Strategy Research of Shanghai Jiao Tong University China Hospital Development Institute, Shanghai 200011, P.R. China
Published online on: December 4, 2017 https://doi.org/10.3892/ijmm.2017.3306
Pages: 995-1002

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Sevoflurane, an inhalational anesthetic, is extensively used during oral cancer surgery. However, the effect of sevoflurane on head and neck squamous cell carcinoma (HNSCC) remains unclear. The objective of the present study was to investigate the effects of sevoflurane on the proliferation, apoptosis and invasion in HNSCC cell lines and the underlying molecular mechanism. The Cell Counting Kit-8 assay was used to evaluate cell proliferation. Apoptosis was analyzed by flow cytometry. Cell invasion was evaluated using the Transwell invasion assay. The expression levels of Akt, p-Akt (Ser473), hypoxia‑inducible factor-1α (HIF-1α), Fas and Bcl-2 were measured by western blotting. Significant inhibition of cell proliferation and induction of apoptosis were observed in FaDu and CAL-27 cells following sevoflurane treatment. The expression of Akt, p-Akt (Ser473) and Bcl-2 was supressed, while that of Fas was significantly increased, which was partly associated with the activation of the HIF-1α pathway. In addition, the results revealed a statistically significant inhibition of cell invasion in the FaDu cell line following exposure to 2 and 4% sevoflurane for 2, 4, 6 and 8 h. Therefore, the present study demonstrated that sevoflurane decreased the malignant behavior of HNSCC cell lines in vitro, which was associated with activation of the HIF-1α pathway.

View Figures

View References

1	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
2	Fuller CD, Wang SJ, Thomas CR Jr, Hoffman HT, Weber RS and Rosenthal DI: Conditional survival in head and neck squamous cell carcinoma: results from the SEER dataset 1973-1998. Cancer. 109:1331–1343. 2007. View Article : Google Scholar : PubMed/NCBI
3	Kalavrezos N and Bhandari R: Current trends and future perspectives in the surgical management of oral cancer. Oral oncol. 46:429–432. 2010. View Article : Google Scholar : PubMed/NCBI
4	Niwa H, Rowbotham DJ, Lambert DG and Buggy DJ: Can anesthetic techniques or drugs affect cancer recurrence in patients undergoing cancer surgery? J Anesth. 27:731–741. 2013. View Article : Google Scholar : PubMed/NCBI
5	Snyder GL and Greenberg S: Effect of anaesthetic technique and other perioperative factors on cancer recurrence. Br J Anaesth. 105:106–115. 2010. View Article : Google Scholar : PubMed/NCBI
6	López Correa T, Sánchez Hernández MV, Briz Sánchez E and Estévez Amores FI: Anesthesia in head and neck paragangliomas. Acta Otorrinolaringol Esp. 60(Suppl 1): 76–79. 2009.In Spanish.
7	Juckenhöfel S, Feisel C, Schmitt HJ and Biedler A: TIVA with propofol-remifentanil or balanced anesthesia with sevoflurane-fentanyl in laparoscopic operations. Hemodynamics, awakening and adverse effects. Anaesthesist. 48:807–812. 1999.In German. View Article : Google Scholar
8	Jun R, Gui-he Z, Xing-xing S, Hui Z and Li-xian X: Isoflurane enhances malignancy of head and neck squamous cell carcinoma cell lines: a preliminary study in vitro. Oral Oncol. 47:329–333. 2011. View Article : Google Scholar : PubMed/NCBI
9	Saunders MI and Rojas AM: Management of cancer of the head and neck - a cocktail with your PORT? N Engl J Med. 350:1997–1999. 2004. View Article : Google Scholar : PubMed/NCBI
10	Vartanian JG, Carvalho AL, Carvalho SM, Mizobe L, Magrin J and Kowalski LP: Pectoralis major and other myofascial/myocutaneous flaps in head and neck cancer reconstruction: experience with 437 cases at a single institution. Head Neck. 26:1018–1023. 2004. View Article : Google Scholar : PubMed/NCBI
11	Spriano G, Pellini R and Roselli R: Pectoralis major myocutaneous flap for hypopharyngeal reconstruction. Plast Reconstr Surg. 110:1408–1413. 2002. View Article : Google Scholar : PubMed/NCBI
12	Engroff SL: Fibula flap reconstruction of the condyle in disarticulation resections of the mandible: a case report and review of the technique. Oral Surg oral Med Oral Pathol Oral Radiol Endod. 100:661–665. 2005. View Article : Google Scholar : PubMed/NCBI
13	Zhang L, Zhang J, Yang L, Dong Y, Zhang Y and Xie Z: Isoflurane and sevoflurane increase interleukin-6 levels through the nuclear factor-kappa B pathway in neuroglioma cells. Br J Anaesth. 110(Suppl 1): i82–i91. 2013. View Article : Google Scholar : PubMed/NCBI
14	Sun Y, Li QF, Zhang Y, Hu R and Jiang H: Isoflurane preconditioning increases survival of rat skin random-pattern flaps by induction of HIF-1α expression. Cell Physiol Biochem. 31:579–591. 2013. View Article : Google Scholar
15	Benzonana LL, Perry NJ, Watts HR, Yang B, Perry IA, Coombes C, Takata M and Ma D: Isoflurane, a commonly used volatile anesthetic, enhances renal cancer growth and malignant potential via the hypoxia-inducible factor cellular signaling pathway in vitro. Anesthesiology. 119:593–605. 2013. View Article : Google Scholar : PubMed/NCBI
16	Heaney A and Buggy DJ: Can anaesthetic and analgesic techniques affect cancer recurrence or metastasis? Br J Anaesth. 109(Suppl 1): i17–i28. 2012. View Article : Google Scholar
17	Exadaktylos AK, Buggy DJ, Moriarty DC, Mascha E and Sessler DI: Can anesthetic technique for primary breast cancer surgery affect recurrence or metastasis? Anesthesiology. 105:660–664. 2006. View Article : Google Scholar : PubMed/NCBI
18	Biki B, Mascha E, Moriarty DC, Fitzpatrick JM, Sessler DI and Buggy DJ: Anesthetic technique for radical prostatectomy surgery affects cancer recurrence: a retrospective analysis. Anesthesiology. 109:180–187. 2008. View Article : Google Scholar : PubMed/NCBI
19	Loop T, Scheiermann P, Doviakue D, Musshoff F, Humar M, Roesslein M, Hoetzel A, Schmidt R, Madea B, Geiger KK, et al: Sevoflurane inhibits phorbol-myristate-acetate-induced activator protein-1 activation in human T lymphocytes in vitro: potential role of the p38-stress kinase pathway. Anesthesiology. 101:710–721. 2004. View Article : Google Scholar : PubMed/NCBI
20	Dong Y, Zhang G, Zhang B, Moir RD, Xia W, Marcantonio ER, Culley DJ, Crosby G, Tanzi RE and Xie Z: The common inhalational anesthetic sevoflurane induces apoptosis and increases beta-amyloid protein levels. Arch Neurol. 66:620–631. 2009. View Article : Google Scholar : PubMed/NCBI
21	Roesslein M, Frick M, Auwaerter V, Humar M, Goebel U, Schwer C, Geiger KK, Pahl HL, Pannen BH and Loop T: Sevoflurane-mediated activation of p38-mitogen-activated stress kinase is independent of apoptosis in Jurkat T-cells. Anesth Analg. 106:1150–1160. 2008. View Article : Google Scholar
22	Kvolik S, Glavas-Obrovac L, Bares V and Karner I: Effects of inhalation anesthetics halothane, sevoflurane, and isoflurane on human cell lines. Life Sci. 77:2369–2383. 2005. View Article : Google Scholar : PubMed/NCBI
23	Kvolik S, Dobrosevic B, Marczi S, Prlic L and Glavas-Obrovac L: Different apoptosis ratios and gene expressions in two human cell lines after sevoflurane anaesthesia. Acta Anaesthesiol Scand. 53:1192–1199. 2009. View Article : Google Scholar : PubMed/NCBI
24	Liang H, Gu MN, Yang CX, Wang HB, Wen XJ and Zhou QL: Sevoflurane inhibits proliferation, induces apoptosis, and blocks cell cycle progression of lung carcinoma cells. Asian Pac J Cancer Prev. 12:3415–3420. 2011.PubMed/NCBI
25	Owen-Schaub L, Chan H, Cusack JC, Roth J and Hill LL: Fas and Fas ligand interactions in malignant disease. Int J oncol. 17:5–12. 2000.PubMed/NCBI
26	Nagata S: Apoptosis by death factor. Cell. 88:355–365. 1997. View Article : Google Scholar : PubMed/NCBI
27	Owen-Schaub LB, van Golen KL, Hill LL and Price JE: Fas and Fas ligand interactions suppress melanoma lung metastasis. J Exp Med. 188:1717–1723. 1998. View Article : Google Scholar : PubMed/NCBI
28	Algeciras-Schimnich A, Shen L, Barnhart BC, Murmann AE, Burkhardt JK and Peter ME: Molecular ordering of the initial signaling events of CD95. Mol Cell Biol. 22:207–220. 2002. View Article : Google Scholar
29	Möller P, Koretz K, Leithäuser F, Brüderlein S, Henne C, Quentmeier A and Krammer PH: Expression of APo-1 (CD95), a member of the NGF/TNF receptor superfamily, in normal and neoplastic colon epithelium. Int J Cancer. 57:371–377. 1994. View Article : Google Scholar : PubMed/NCBI
30	Hill LL, Ouhtit A, Loughlin SM, Kripke ML, Ananthaswamy HN and Owen-Schaub LB: Fas ligand: a sensor for DNA damage critical in skin cancer etiology. Science. 285:898–900. 1999. View Article : Google Scholar : PubMed/NCBI
31	Zörnig M, Grzeschiczek A, Kowalski MB, Hartmann KU and Möröy T: Loss of Fas/Apo-1 receptor accelerates lymphomagenesis in E mu L-MYC transgenic mice but not in animals infected with MoMuLV. Oncogene. 10:2397–2401. 1995.PubMed/NCBI
32	Gordon N and Kleinerman ES: The role of Fas/FasL in the metastatic potential of osteosarcoma and targeting this pathway for the treatment of osteosarcoma lung metastases. Cancer Treat Res. 152:497–508. 2009. View Article : Google Scholar
33	Leber B, Geng F, Kale J and Andrews DW: Drugs targeting Bcl-2 family members as an emerging strategy in cancer. Expert Rev Mol Med. 12:e282010. View Article : Google Scholar : PubMed/NCBI
34	Gong JS, Yao YT, Fang NX and Li LH: Sevoflurane postconditioning attenuates reperfusion-induced ventricular arrhythmias in isolated rat hearts exposed to ischemia/reperfusion injury. Mol Biol Rep. 39:6417–6425. 2012. View Article : Google Scholar : PubMed/NCBI
35	Wang JK, Yu LN, Zhang FJ, Yang MJ, Yu J, Yan M and Chen G: Postconditioning with sevoflurane protects against focal cerebral ischemia and reperfusion injury via PI3K/Akt pathway. Brain Res. 1357:142–151. 2010. View Article : Google Scholar : PubMed/NCBI
36	Li QF, Zhu YS and Jiang H: Isoflurane preconditioning activates HIF-1alpha, iNOS and Erk1/2 and protects against oxygen-glucose deprivation neuronal injury. Brain Res. 1245:26–35. 2008. View Article : Google Scholar : PubMed/NCBI
37	Li QF, Wang XR, Yang YW and Su DS: Up-regulation of hypoxia inducible factor 1alpha by isoflurane in Hep3B cells. Anesthesiology. 105:1211–1219. 2006. View Article : Google Scholar : PubMed/NCBI
38	McCawley LJ and Matrisian LM: Matrix metalloproteinases: multifunctional contributors to tumor progression. Mol Med Today. 6:149–156. 2000. View Article : Google Scholar : PubMed/NCBI
39	Sternlicht MD and Werb Z: How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol. 17:463–516. 2001. View Article : Google Scholar : PubMed/NCBI
40	Hurmath FK, Mittal M, Ramaswamy P, Umamaheswara Rao QS and Dalavaikodihalli Nanjaiah N: Sevoflurane and thiopental preconditioning attenuates the migration and activity of MMP-2 in U87MG glioma cells. Neurochem Int. 94:32–38. 2016. View Article : Google Scholar : PubMed/NCBI
41	Xu YJ, Li SY, Cheng Q, Chen WK, Wang SL, Ren Y and Miao CH: Effects of anaesthesia on proliferation, invasion and apoptosis of Lovo colon cancer cells in vitro. Anaesthesia. 71:147–154. 2016. View Article : Google Scholar
42	Gottschalk A, Sharma S, Ford J, Durieux ME and Tiouririne M: The role of the perioperative period in recurrence after cancer surgery (Review). Anesth Analg. 110:1636–1643. 2010. View Article : Google Scholar : PubMed/NCBI